261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC acquired a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 261,344 shares of the company’s stock, valued at approximately $13,263,000. TimesSquare Capital Management LLC owned about 0.43% of Enliven Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ELVN. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the first quarter worth $38,000. State of Wyoming acquired a new stake in shares of Enliven Therapeutics in the second quarter valued at about $96,000. FNY Investment Advisers LLC purchased a new position in shares of Enliven Therapeutics in the second quarter worth about $126,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

ELVN has been the subject of several research reports. The Goldman Sachs Group upped their price objective on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Stifel Nicolaus raised their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. JonesTrading boosted their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. HC Wainwright upped their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Finally, Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $72.67.

Enliven Therapeutics Trading Up 1.2%

Shares of ELVN opened at $59.53 on Tuesday. Enliven Therapeutics, Inc. has a 12-month low of $14.78 and a 12-month high of $62.32. The firm has a 50-day moving average price of $51.42 and a 200 day moving average price of $41.13. The firm has a market capitalization of $4.36 billion, a P/E ratio of -35.65 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the sale, the director owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $52.64, for a total value of $316,787.52. Following the completion of the transaction, the chief financial officer owned 46,054 shares in the company, valued at $2,424,282.56. This represents a 11.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 190,831 shares of company stock worth $10,991,723 in the last 90 days. Insiders own 3.00% of the company’s stock.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.